AI assistant
PAINCHEK LTD — Investor Presentation 2021
Nov 21, 2021
65534_rns_2021-11-21_3a5d0ac4-ad84-4d9a-8191-be7328886720.pdf
Investor Presentation
Open in viewerOpens in your device viewer
ASX ANNOUNCEMENT 22 NOVEMBER 2021
==> picture [182 x 42] intentionally omitted <==
PainChek to present at NWR Virtual Healthcare
Day
PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart phone-based pain assessment and monitoring application, is pleased to announce that CEO Philip Daffas will be presenting at the NWR Virtual Healthcare Day at 12pm (midday) AEDT on Wednesday 24 November 2021.
Investors can register for the session at the following link: https://us02web.zoom.us/webinar/register/WN_HHKhJVGdS_2xul4ugsEy1w
After registering, you will receive a confirmation email containing information about joining the webinar. A recording will be made available shortly after the conclusion of the webinar at the same link above.
Investors are invited to submit questions prior to the webinar to [email protected]
For more information on the conference click here: https://nwrconference.webflow.io/
This release has been authorized by CEO Philip Daffas.
For more information: Sally McDow Philip Daffas Company Secretary, PainChek CEO, PainChek [email protected] [email protected] 0420 213 035 0406 537 235
About PainChek®
PainChek® Ltd is an Australian based company that develops pain assessment technologies.
PainChek® is a smart phone based medical device using artificial intelligence and smart automation to identify and quantify pain and update medical records in the cloud in real-time.
Firstly, PainChek® analyses in real-time images from a three second video capture for the presence of facial expressions indicative of pain and records those that are present.
Next, the caregiver uses PainChek® to record their observations of other pain related behaviours that complete the assessment. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to monitor the effect of medication and treatment over time.
PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for Children who have not yet learnt to speak.
ABN 21 146 035 127 401, 35 Lime Street, Sydney, NSW, 2000
P: +61 8 9388 8290 E: [email protected] W: painchek.com
The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.
To find out more, visit www.painchek.com
ABN 21 146 035 127 401, 35 Lime Street, Sydney, NSW, 2000
P: +61 8 9388 8290 E: [email protected] W: painchek.com